Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Biomarkers of pulmonary hypertension in patients with scleroderma: a case–control study

Fig. 1

Placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) levels in patients with or without pulmonary hypertension (PH). a PlGF (median, 25 [interquartile range {IQR}, 16.3–31.0] pg/ml vs. 19.1 [15.3–22.9] pg/ml; p = 0.02) is significantly higher in patients with scleroderma with PH than in those with scleroderma without PH across the whole cohort at the later time point (n = 33 PH, n = 38 non-PH) (b) sFlt-1 (median, 102 [IQR, 88–149] pg/ml vs. 90 [66–121] pg/ml; p = 0.02) is significantly higher in patients with scleroderma with PH than in those with scleroderma without PH across the whole cohort (n = 37 PH, n = 40 non-PH)

Back to article page